UBS Group AG - TAKEDA PHARMACEUTICAL CO LTD ownership

TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 392 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q1 2019. The put-call ratio across all filers is 1.12 and the average weighting 0.3%.

Quarter-by-quarter ownership
UBS Group AG ownership history of TAKEDA PHARMACEUTICAL CO LTD
ValueSharesWeighting
Q3 2023$794,927
-75.9%
51,385
-75.5%
0.00%
-100.0%
Q2 2023$3,297,607
+142.6%
209,905
+154.5%
0.00%
Q1 2023$1,359,039
-25.0%
82,466
-29.0%
0.00%
-100.0%
Q4 2022$1,811,972
+12.7%
116,152
-6.3%
0.00%0.0%
Q3 2022$1,608,000
+0.2%
124,004
+8.5%
0.00%0.0%
Q2 2022$1,605,000
+5.3%
114,301
+7.4%
0.00%0.0%
Q1 2022$1,524,000
-90.4%
106,400
-90.8%
0.00%
-75.0%
Q4 2021$15,803,000
+120.0%
1,159,480
+164.4%
0.00%
+100.0%
Q3 2021$7,182,000
+1.5%
438,509
+4.3%
0.00%0.0%
Q2 2021$7,073,000
-10.6%
420,317
-3.0%
0.00%
-33.3%
Q1 2021$7,913,000
+332.6%
433,382
+331.1%
0.00%
+200.0%
Q4 2020$1,829,000
+22.8%
100,523
+20.5%
0.00%0.0%
Q3 2020$1,489,000
-4.5%
83,444
-4.0%
0.00%0.0%
Q2 2020$1,559,000
+42.8%
86,946
+20.9%
0.00%0.0%
Q1 2020$1,092,000
-22.4%
71,940
+0.9%
0.00%
Q4 2019$1,407,000
+9.8%
71,264
-4.3%
0.00%
Q3 2019$1,281,000
-18.0%
74,502
-15.7%
0.00%
-100.0%
Q2 2019$1,563,000
-65.9%
88,350
-60.7%
0.00%
-50.0%
Q1 2019$4,577,000
-97.3%
224,717
-97.8%
0.00%
-97.4%
Q4 2018$170,699,00010,148,5960.08%
Other shareholders
TAKEDA PHARMACEUTICAL CO LTD shareholders Q1 2019
NameSharesValueWeighting ↓
Blackcrane Capital, LLC 30,201$3,149,00019.29%
MANAGED ASSET PORTFOLIOS, LLC 1,399,878$20,046,0002.75%
Clean Yield Group 251,220$3,597,0001.27%
Mondrian Investment Partners LTD 4,319,715$60,476,0001.24%
Sippican Capital Advisors 80,490$1,153,0000.96%
TFG Asset Management GP Ltd 1,275,656$18,268,0000.83%
Lumbard & Kellner, LLC 132,516$1,898,0000.74%
BRANDES INVESTMENT PARTNERS, LP 2,109,846$30,213,0000.65%
CAUSEWAY CAPITAL MANAGEMENT LLC 1,601,046$22,927,0000.55%
Ridgewood Investments LLC 33,378$478,0000.31%
View complete list of TAKEDA PHARMACEUTICAL CO LTD shareholders